Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer.

Breast Cancer Res Treat · 2023 · PMC10147793 · PMID 36897465

Europe PMC DOI

hedged sentence

0.2980

closest p · 6.0× alpha

0.2980

boldest claim

The sentences

did not reach statistical significancep = 0.298not close (p > 0.1)

While there were different rates of pCR in the lymph nodes in the randomized groups (4.3% in Group B vs 13.6% in Group C), they did not reach statistical significance ( p = 0.298).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.